PDIA3 and glioblastoma: Transcriptome analysis, single cell sequencing, cytokine analysis, and T cell signal transduction analysis show that editing PDIA3 in T cells can enhance the effector function, and engineered PDIA3 mutant EGFRvIII chimeric antigen T cells are more effective in antigen-specific killing of human glioblastoma cells.